Advax-adjuvanted killed Japanese encephalitis virus (JEV) vaccine is safe in pregnant mares and in foals and induces robust immunological memory

Helle Bielefeldt-Ohmann1,2, Natalie A. Prow1,2, Wenqi Wang1, Cindy S.E. Tan1,2,3, Mitchell Coyle1, Alysha Douma1, Jody Habsan-Peters1,2,3, Lisa Kidd1, Roy A. Hall2,3 and Nikolai Petrovsky1,2,3
1School of Veterinary Science, Australia
2Australian Infectious Diseases Research Centre, Australia
3School of Biochemistry & Molecular Biosciences, Australia
4University of Queensland, Australia
5Flinders Medical Centre, Adelaide, South Australia
6Flinders Medical Centre and Flinders University, South Australia

In 2011, following severe flooding in Eastern Australia, an unprecedented epidemic of equine encephalitis occurred in South-Eastern Australia, caused by Murray Valley encephalitis virus (MVEV) and a new variant strain of Kunjin virus, a subtype of West Nile virus (WNVKUN). This prompted us to assess whether a delta inulin-adjuvanted, inactivated cell culture-derived Japanese encephalitis virus (JEV) vaccine (JE-ADVAX<sub>TM</sub>) could be used in horses, including pregnant mares and foals, to not only induce immunity to JEV, but also elicit cross-protective antibodies against MVEV and WNVKUN. Foals, 74-152 days old, received two injections of JE-ADVAX<sub>TM</sub>. The vaccine was safe and well-tolerated and induced a strong JEV-neutralizing antibody response in all foals. MVEV and WNVKUN antibody cross-reactivity was seen in 33% and 42% of the immunized foals, respectively. JE-ADVAX<sub>TM</sub> was also safe and well-tolerated in pregnant mares and induced high JEV-neutralizing titters. The neutralizing activity was passively transferred to their foals via colostrum. Foals that acquired passive immunity to JEV via maternal antibodies then were immunized with JE-ADVAX<sub>TM</sub> at 36-83 days of age, showed evidence of maternal antibody interference with low peak antibody titers post-immunization when compared to immunized foals of JEV-naïve dams. Nevertheless, when given a single JE-ADVAX<sub>TM</sub> booster immunization as yearlings, these animals developed a rapid and robust JEV-neutralizing antibody response, indicating that they were successfully primed to JEV when immunized as foals, despite the presence of maternal antibodies. Overall, JE-ADVAX<sub>TM</sub> appears safe and well-tolerated in pregnant mares and young foals and induces protective levels of JEV neutralizing antibodies with partial cross-neutralization of MVEV and WNV<sub>KUN</sub>.

biohmpathology@gmail.com

Helle Bielefeldt-Ohmann et al., J Vaccines Vaccin 2015, 6:3
http://dx.doi.org/10.4172/2157-7560.S1.024